Affiliation:
1. University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
Abstract
ABSTRACT
The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC
50
and MIC
90
) were both 0.25 μg/ml, irrespective of methicillin resistance. MIC
50
and MIC
90
were 0.25 and 0.5 μg/ml for vancomycin-susceptible enterococci and 1 and 2 μg/ml for vancomycin-resistant enterococci, respectively.
Streptococcus pneumoniae
, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by ≤0.12 μg/ml.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference11 articles.
1. Barrett, J. F. 2005. Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs6:781-790.
2. Performance standards for antimicrobial susceptibility testing. 2005
3. In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and
Corynebacterium
spp
4. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant
Staphylococcus aureus
5. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother.53:797-803.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献